Related Experiment Videos
Lipid lowering therapy leads to a reduction in sodium-lithium countertransport activity
S J Carr1, T H Thomas, M F Laker
1Department of Medicine and Nephrology, Freeman Hospital, Newcastle upon Tyne, U.K.
Insights
Erythrocyte sodium-lithium countertransport (SLC) levels were elevated in patients with hyperlipidaemia before treatment. Lipid-lowering therapy normalized SLC, suggesting a link between triglycerides and SLC in hyperlipidaemia.
Area of Science:
- Biochemistry
- Cardiovascular Medicine
- Human Physiology
Background:
- Erythrocyte sodium-lithium countertransport (SLC) is a marker linked to essential hypertension.
- Hyperlipidaemia, characterized by elevated lipids, is a significant risk factor for cardiovascular disease.
- The relationship between SLC and hyperlipidaemia requires further investigation.
Purpose of the Study:
- To investigate the association between erythrocyte sodium-lithium countertransport (SLC) and hyperlipidaemia.
- To determine the effect of lipid-lowering therapy on SLC levels in patients with hyperlipidaemia.
- To explore potential differences in the mechanisms underlying SLC elevation in hyperlipidaemia versus essential hypertension.
Main Methods:
- Erythrocyte sodium-lithium countertransport (SLC) was measured in 17 patients.
- Patients had either combined hyperlipidaemia or hypercholesterolaemia.
- Measurements were taken before and after lipid-lowering therapy.
Main Results:
- Before treatment, SLC levels were related to serum triglyceride levels and elevated in combined hyperlipidaemia.
- After lipid-lowering therapy, SLC levels normalized.
- The observed changes in SLC were correlated with changes in serum triglyceride levels.
Conclusions:
- Elevated erythrocyte sodium-lithium countertransport (SLC) is associated with hyperlipidaemia, particularly when associated with high triglycerides.
- Lipid-lowering therapy effectively reduces SLC levels in hyperlipidaemic patients.
- The mechanisms linking SLC to hyperlipidaemia appear distinct from those linking SLC to essential hypertension.
Abstract:
Erythrocyte sodium-lithium countertransport (SLC) was measured in 17 patients with either combined hyperlipidaemia or hypercholesterolaemia before and after lipid lowering therapy. Before treatment SLC related to the serum triglyceride level and was increased in combined hyperlipidaemia. After treatment the SLC had returned to normal and the change in SLC was related to the change in serum triglyceride levels. Raised SLC is associated with essential hypertension but is not related to blood pressure. Therefore, the association of raised SLC with hyperlipidaemia and essential hypertension appears to have different underlying mechanisms.